AUTHOR=Kamiya Kazutaka , Shimizu Kimiya , Igarashi Akihito , Kitazawa Yoshihiro , Kojima Takashi , Nakamura Tomoaki , Ichikawa Kazuo , Fukuoka Sachiko , Fujimoto Kahoko ,  The Japan ICL Study Group 

TITLE=A Nationwide Multicenter Study on 1-Year Outcomes of Posterior Chamber Phakic Intraocular Lens Implantation for Low Myopia

JOURNAL=Frontiers in Medicine

VOLUME=Volume 9 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.762153

DOI=10.3389/fmed.2022.762153

ISSN=2296-858X

ABSTRACT=PURPOSE: To assess the nationwide multicenter outcomes of posterior chamber phakic intraocular lens implantation with a central hole (EVO-ICL, STAAR Surgical) for patients with low myopia.
METHODS: This multicenter study comprised 172 eyes of 111 consecutive patients undergoing hole ICL implantation to correct low myopia and myopic astigmatism (manifest spherical equivalent; -3 diopters (D) or less) at 7 nationwide major surgical facilities. We retrospectively determined safety, efficacy, predictability, stability, and adverse events at 1 week, 1, 3, 6, and 12 months postoperatively, and at the final visit. 
RESULTS: The mean follow-up period was 1.4 ± 1.0 years. Uncorrected and corrected visual acuities were -0.17 ± 0.12 and -0.24 ± 0.07 logMAR at 1 year postoperatively. At 1 year postoperatively, 91% and 100% of eyes were within 0.5 and 1.0 D, respectively, of the targeted correction. No significant manifest refraction changes of -0.07 ± 0.26 D occurred from 1 week to 1 year. No vision-threatening complications occurred at any time in this series.
CONCLUSIONS: According to our experience, the EVO-ICL performed well without significant complications throughout the 1-year observation period, even for the correction of low myopia. It is suggested that current ICL implantation is one of the viable surgical options for correcting low myopia.